



## Novogen Company Profile

### Overview

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney. Novogen has a diversified portfolio of development candidates targeting a range of cancer types.

The lead program, GDC-0084, is being developed to treat glioblastoma, the most common and most aggressive form of brain cancer. Licensed from Genentech in late 2016, GDC-0084 will enter phase II human trials in the fourth quarter of calendar 2017.

Cantrixil has been derived from an internal drug discovery program and commenced a phase I human trial in ovarian cancer in December 2016. Novogen also has an early-stage discovery program focused on the cytoskeleton of the cancer cell, which is co-funded via a \$3 million CRC-P grant that was awarded in early 2016.

For more information, please visit: [novogen.com](http://novogen.com)

### Speaker Profile

#### Dr James Garner, MA, MBA, MBBS, BSC (HONS) CEO and Executive Director



Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.

Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Novogen in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.